Recon: FDA approves Axsome’s depression drug Auvelity after year-long wait; Gilead scores first global approval for HIV treatment
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy